Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Has Average Price Target of $103.00 According to Brokerages

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have been given an average recommendation of “Hold” by the twenty-two ratings firms that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, fourteen have issued a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $103.00.

Several equities research analysts have weighed in on the stock. Canaccord Genuity Group increased their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a report on Monday, August 10th. Zacks Research raised shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 25th. Wall Street Zen cut shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a research note on Thursday, August 6th. Finally, Sanford C. Bernstein lifted their target price on Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a report on Thursday, August 6th.

Zimmer Biomet Price Performance

Shares of ZBH opened at $91.08 on Tuesday. The stock has a market cap of $17.37 billion, a P/E ratio of 22.16, a price-to-earnings-growth ratio of 1.72 and a beta of 0.47. Zimmer Biomet has a 1 year low of $79.12 and a 1 year high of $106.88. The stock’s 50-day moving average price is $96.23 and its two-hundred day moving average price is $91.26. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. The company had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.Zimmer Biomet’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the business posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, equities analysts predict that Zimmer Biomet will post 8.54 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

Insider Activity

In related news, insider Kevin R. Thornal sold 5,691 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Chad Phipps sold 3,000 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the sale, the insider directly owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. The trade was a 4.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 1.28% of the company’s stock.

Institutional Investors Weigh In On Zimmer Biomet

A number of hedge funds and other institutional investors have recently made changes to their positions in ZBH. OMERS ADMINISTRATION Corp bought a new stake in shares of Zimmer Biomet in the second quarter valued at about $922,000. Hsbc Holdings PLC acquired a new position in shares of Zimmer Biomet during the second quarter worth about $35,417,000. Morningstar Investment Management LLC grew its holdings in shares of Zimmer Biomet by 235.4% during the fourth quarter. Morningstar Investment Management LLC now owns 57,865 shares of the medical equipment provider’s stock worth $5,204,000 after buying an additional 40,610 shares in the last quarter. Legal & General Group Plc acquired a new stake in Zimmer Biomet in the 2nd quarter valued at approximately $126,167,000. Finally, Rakuten Investment Management Inc. bought a new stake in Zimmer Biomet in the 2nd quarter valued at approximately $2,945,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc (NYSE:ZBH) is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.